Source-grounded facts extracted from BIO-TECHNE Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIO-TECHNE Corp reported financial results for quarter and nine months ended March 31, 2026.
“A copy of the press release issued by Bio-Techne Corporation on May 6, 2026, describing the results of operations for the quarter and nine months ended March 31, 2026, and its financial condition as of March 31, 2026 is attached hereto as Exhibit 99.1.”
Amy Herr was appointed as Independent Director at BIO-TECHNE Corp.
“On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.”
BIO-TECHNE Corp reported the third quarter ending March 31, 2024 results: revenue $303.4 million, EPS $0.31.
“reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights ● Third quarter organic revenue increased by 2% (3% reported) to $303.4 million. ● GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. ● Strong commercial execution in”
Dr. Judith Klimovsky was appointed as Director at BIO-TECHNE Corp.
“On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.”
BIO-TECHNE Corp reported financial results for second quarter ended December 31, 2023.
“A copy of the press release issued by Bio-Techne Corporation on February 1, 2024, describing the results of operations for the quarter ended December 31, 2023, and its financial condition as of December 31, 2023 is attached hereto as Exhibit 99.1.”
Dr. Matthew McManus was appointed as President – Diagnostics and Genomics Segment at BIO-TECHNE Corp.
“On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.